Eagle's Eye View: Your Weekly CV Update From ACC.org Key Takeaways from ACC.25 Major Trials and Presentations
6 snips
Apr 2, 2025 Dive into groundbreaking cardiovascular research from the recent conference in Chicago. Discover how TAVR compares to surgical aortic valve replacement with impressive five-year results. Learn about the advantages of clopidogrel over aspirin after a PCI and how dapagliflozin benefits older heart failure patients during valve procedures. Plus, see how semaglutide enhances outcomes for peripheral artery disease. Rivaroxaban shines in post-MI settings, alongside innovative dosing strategies for anticoagulants in active cancer patients.
AI Snips
Chapters
Transcript
Episode notes
TAVR Equals SAVR at 5 Years
- Five-year data show TAVR is as effective as SAVR in low-risk severe aortic stenosis patients.
- TAVR also offers less immediate morbidity, proving its modern excellence.
Clopidogrel Better Than Aspirin After PCI
- Clopidogrel monotherapy after PCI reduces major cardiovascular events compared to aspirin.
- It notably lowers both myocardial infarction and all-cause death in high-risk patients.
Dapagliflozin Benefits Post-TAVI Heart Failure
- Dapagliflozin significantly reduces worsening heart failure post-TAVI in patients with heart failure or diabetes.
- It cuts heart failure events by 37%, marking a major advance in valvular heart disease treatment.